楚天科技(300358.SZ):2024年公司本部出口新簽訂單首次突破10億
格隆匯2月19日丨楚天科技(300358.SZ)於近期投資者關係活動表示,2024年,公司本部出口新簽訂單首次突破10億人民幣,在歐洲等市場也取得了良好突破。為應對市場環境變化及適應新的競爭態勢,公司一直在加強對拓展國際業務的資源投入,在十多個國家和地區設立了SSC(銷售服務中心),隨着公司對海外市場的深耕,公司國際訂單信息與合同金額都有明顯增長,未來規劃海外市場訂單佔比超過國內訂單。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.